SETD2 and renal cell adenocarcinoma: Our results identify a highly conserved DNA hypermethylation phenotype induced by SETD2 inactivation that functionally modulates the gene expression program of renal cell cancers, suggesting that DNA demethylating agents represent a potential rational therapy to target SETD2 loss of function tumors.